dr. A.J. van der Wekken

pulmonary oncologist

No picture available
E-mail:
a.j.van.der.wekken umcg.nl

Research

  1. 2020
  2. Koopman, B., Groen, H. J. M., Ligtenberg, M. J. L., Grünberg, K., Monkhorst, K., de Langen, A. J., Boelens, M. C., Paats, M. S., Von der Thüsen, J. H., Dinjens, W. N. M., Solleveld, N., Van Wezel, T., Gelderblom, H., Hendriks, L. E., Speel, E-J. M., Theunissen, T. E., Kroeze, L. I., Mehra, N., Piet, B., ... van Kempen, L. (2020). Multicenter comparison of Molecular Tumor Boards in the Netherlands: definition, composition, methods and targeted therapy recommendations. The Oncologist. https://doi.org/10.1002/onco.13580
  3. Paik, P. K., Felip, E., Veillon, R., Sakai, H., Cortot, A. B., Garassino, M. C., Mazieres, J., Viteri, S., Senellart, H., Van Meerbeeck, J., Raskin, J., Reinmuth, N., Conte, P., Kowalski, D., Cho, B. C., Patel, J. D., Horn, L., Griesinger, F., Han, J-Y., ... Le, X. (2020). Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. New England Journal of Medicine, 383(10), 931-943. https://doi.org/10.1056/NEJMoa2004407
  4. van Veggel, B., Madeira R Santos, J. F. V., Hashemi, S. M. S., Paats, M. S., Monkhorst, K., Heideman, D. A. M., Groves, M., Radonic, T., Smit, E. F., Schuuring, E., van der Wekken, A. J., & de Langen, A. J. (2020). Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer. Lung Cancer, 141, 9-13. https://doi.org/10.1016/j.lungcan.2019.12.013
  5. 2019
  6. 2018
  7. van Veggel, B., van der Wekken, A., Hashemi, S., Cornelissen, R., Monkhorst, K., Heideman, D., Radonic, T., Smit, E. F., Schuuring, E., & De Langen, J. (2018). Osimertinib treatment for patients with EGFR exon 20 insertion positive non-small cell lung cancer. Annals of Oncology, 29(Suppl.8), viii524-viii525. https://doi.org/10.1093/annonc/mdy292.072
  8. 2017
  9. van der Wekken, A. J., Pelgrim, R., 't Hart, N., Werner, N., Mastik, M., Hendriks, L., van der Heijden, E. H., Looijen-Salamon, M., de Langen, A. J., Staal-van den Brekel, J., Riemersma, S., van den Borne, B. E., Speel, E-J. M., Dingemans, A-M. C., Hiltermann, T. J. N., van den Berg, A., Timens, W., Schuuring, E., & Groen, H. J. M. (2017). Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer. Clinical Cancer Research, 23(15), 4251-4258. https://doi.org/10.1158/1078-0432.CCR-16-1631
  10. 2016
  11. 2015
  12. Mellema, W. W., Masen-Poos, L., Smit, E. F., Hendriks, L. E. L., Aerts, J. G., Termeer, A., Goosens, M. J., Smit, H. J. M., van den Heuvel, M. M., Wekken, van der, A. J., Herder, G. J. M., Krouwels, F. H., Stigt, J. A., van den Borne, B. E. E. M., Haitjema, T. J., Staal-Van den Brekel, A. J., van Heemst, R. C., Pouw, E., & Dingemans, A-M. C. (2015). Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer. Lung Cancer, 90(2), 249-254. https://doi.org/10.1016/j.lungcan.2015.09.012
  13. Kuiper, J. L., Hendriks, L. E., Wekken, van der, A. J., de Langen, A. J., Bahce, I., Thunnissen, E., Heideman, D. A. M., Berk, Y., Buijs, E. J. M., Speel, E-J. M., Krouwels, F. H., Smit, H. J. M., Groen, H. J. M., Dingemans, A-M. C., & Smit, E. F. (2015). Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis. Lung Cancer, 89(3), 255-261. https://doi.org/10.1016/j.lungcan.2015.05.023
  14. 2013
  15. 2012

ID: 35892471